Company intelligence / Profile preview

Adeptio Pharmaceuticals

London, England, United Kingdomadeptiopharmaceuticals.com ↗

Ownership: Private
Development stage: Other

Overview

Adeptio Pharmaceuticals has a robust clinical pipeline with 78 clinical-stage projects, including 32 programs in Phase 3 or regulatory submission. Their portfolio covers both new molecular entities and expanded indications for existing therapies, primarily focused on difficult-to-treat diseases and immunization. The company has active programs in immunology, neurology, and vaccines, with several candidates advancing in late-stage clinical trials. No commercial launches were referenced.

Therapeutic areas: NeurologyPulmonologyInfectious DiseasesDermatologyImmunology
Modalities: Small moleculeBiologicVaccine
Industry: Biotech

Drug pipeline

2 assets

dihydrotetrabenazine

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Adeptio Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adeptio Pharmaceuticals.

Explore the full profile